Zhang H, Liang J L, Chen S Y, Wang Z J, Yang F, Cui F, Ren Y T, Liu W X, Sun Z S, Huang X S
Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China.
Zhonghua Yi Xue Za Zhi. 2018 Sep 4;98(33):2628-2631. doi: 10.3760/cma.j.issn.0376-2491.2018.33.003.
To investigate all coding regions of amyotrophic lateral sclerosis (ALS)-related gene Senataxin (SETX) in sporadic amyotrophic lateral sclerosis patients of Chinese origin. From January 2010 to December 2014, the peripheral venous blood samples and clinical data were collected from 311 patients with sporadic amyotrophic lateral sclerosis (SALS) and 311 healthy controls who were of Chinese ancestry from the Department of Neurology, Chinese PLA General Hospital.Genomic DNA was extracted from peripheral venous blood of all participants using standard methods. The coding regions of SETX were amplified by polymerase chain reaction (PCR) and screened for mutations using next-generation sequencing technology. The online software SIFT and PolyPhen-2 were used to analyze the conservation of an altered amino acid and predict the potential pathogenicity of identified mutations. The SPSS 22.0 software was used to analyze the clinical feature of all participants. Tenkinds of rare and one novel nonsynonymous mutations were identified and were absent in 311 controls. Twelve (3.86%) patients carried one SETX gene mutation. Five (1.61%) out of above-mentioned 12 patients carried highly pathogenic mutations including p. Pro1868Leu (c.5603G>A), p. Pro1331Leu (c.3992G>A), p. Glu756Val (c.2267T>A), p. Leu564Val (c.1690A>C), and p. Asn144Ser (c.431T>C). Patients carried SETX mutations were not different from other patients in onset age. Mutations in SETX are likely to be a pathogenesis for Chinese sporadic amyotrophic lateral sclerosis.
研究中国散发性肌萎缩侧索硬化症(ALS)患者中与肌萎缩侧索硬化症相关基因Senataxin(SETX)的所有编码区。2010年1月至2014年12月,从中国人民解放军总医院神经内科收集了311例散发性肌萎缩侧索硬化症(SALS)患者和311例具有中国血统的健康对照者的外周静脉血样本及临床资料。采用标准方法从所有参与者的外周静脉血中提取基因组DNA。通过聚合酶链反应(PCR)扩增SETX的编码区,并使用下一代测序技术筛选突变。使用在线软件SIFT和PolyPhen-2分析氨基酸改变的保守性,并预测已鉴定突变的潜在致病性。使用SPSS 22.0软件分析所有参与者的临床特征。共鉴定出10种罕见和1种新的非同义突变,在311例对照者中未发现。12例(3.86%)患者携带1个SETX基因突变。上述12例患者中有5例(1.61%)携带高度致病性突变,包括p.Pro1868Leu(c.5603G>A)、p.Pro1331Leu(c.3992G>A)、p.Glu756Val(c.2267T>A)、p.Leu564Val(c.1690A>C)和p.Asn144Ser(c.431T>C)。携带SETX突变的患者与其他患者在发病年龄上无差异。SETX突变可能是中国散发性肌萎缩侧索硬化症的发病机制之一。